Sanofi has invested $175 million upfront to partner with Johnson & Johnson's Janssen unit on ExPEC9V, a phase 3 vaccine targeting extraintestinal pathogenic E. coli infections.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.